Install Free Gold Price Widget!
Install Free Gold Price Widget!
Install Free Gold Price Widget!
|
- 1861-LB: Efficacy and Safety of HRS9531, a Novel Dual GLP-1 GIP . . .
Introduction: HRS9531, a novel dual GLP-1 and GIP receptor agonist, has shown prominent efficacy in glycemic control and weight loss in phase 1 trials This phase 2 study evaluated the efficacy and safety of HRS9531 in obese adults without diabetes
- Efficacy and safety of HRS9531, a novel dual GLP-1 GIP receptor agonist . . .
Objective: To evaluate the efficacy and safety of HRS9531 compared with placebo in T2DM patients This is a multicenter, randomized, double-blind, placebo-controlled phase 2 trial (NCT05966272) Abbreviations: BMI, body-mass index; QW, once a week; SC, subcutaneous injection
- Kailera reports Zepbound-rivaling weight loss in obesity phase 2
The data suggest HRS9531 has similar efficacy to Eli Lilly’s Zepbound Patients taking the drug, which, like HRS9531, hits GLP-1 and GIP, lost (PDF) 20 9% of their body weight across 36 weeks
- GLP-1 GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity . . .
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have announced compelling topline results from the phase 2 trial (HRS9531-203) evaluating the efficacy and safety of HRS9531, a novel dual glucagon-like peptide-1 (GLP-1) gastric inhibitory polypeptide (GIP) agonist, in individuals with overweight or obesity
- The American Diabetes Association Highlights Innovations in New Drug . . .
HRS9531 is a dual GLP-1 GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, offering a treatment option for individuals with overweight or obesity, as well as type 2 diabetes This Phase 2 study evaluated the efficacy and safety of HRS9531 in obese adults without diabetes
- Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics . . . - BioSpace
HRS9531 Oral presentation: Friday, June 20, 5:45-6:00 p m CT Phase 2 clinical trial of HRS9531 in participants with type 2 diabetes up to 32 weeks Abstract 126-OR: Efficacy and Safety of a Novel Dual GLP-1 GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks;
- 国内首个，恒瑞口服GLP-1 GIP双受体激动剂启动II期临床研究
HRS9531注射液是由恒瑞医药自主研发的GLP-1 GIP双受体激动剂。 胰高糖素样肽-1（GLP-1）和葡萄糖依赖性促胰岛素多肽（GIP）是进食后由肠道合成和分泌的两种肠促胰素，它们在调节血糖和体重方面发挥着重要作用。 越来越多的临床数据表明，GLP-1 GIP双受体激动剂可通过同时激动GLP-1和GIP受体产生互补或协同作用，从而减轻体重和改善血糖控制。 2024年5月，HRS9531作为恒瑞医药具有自主知识产权的GLP-1类创新药组合之一，在大中华区以外的全球范围内开发、生产和商业化的独家权利被有偿许可给了Kailera公司。 通过此次合作，恒瑞医药获得的首付款加里程碑付款总额累计可高达60亿美元，并且取得了Kailera公司19 9%的股权。
- Jiangsu and Kailera report positive topline data for 8mg HRS9531 GLP-1 GIP
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have announced positive topline data from the 8mg dose of Hengrui Pharma’s Phase 2 clinical trial (HRS9531-203) of HRS9531, a GLP-1 GIP receptor dual agonist, in individuals living with obesity or overweight
|
|
|